Conditions: Hepatitis C, Chronic
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1469
Healthy volunteers: no

Brief summary:
This study will evaluate the efficacy and safety of different durations of treatment with PEGASYS combined with ribavirin in patients with CHC genotype 2 or 3 infection who have never previously received interferon (IFN) therapy. The anticipated time on study treatment is 3-12 months and the target sample size is 500+ individuals.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Copegus intervention 2: Copegus intervention 3: peginterferon alfa-2a [Pegasys] intervention 4: peginterferon alfa-2a [Pegasys]
Intervention descriptions: intervention 1: 400mg po bid for 16 weeks intervention 2: 400mg po bid for 24 weeks intervention 3: 180 micrograms sc weekly for 16 weeks intervention 4: 180 micrograms sc weekly for 24 weeks

Protocol document: